Molecular pathways behind acquired obesity : Adipose tissue and skeletal muscle multiomics in monozygotic twin pairs discordant for BMI by van der Kolk, Birgitta W. et al.
ArticleMolecular pathways behind acquired obesity:
Adipose tissue and skeletal muscle multiomics in
monozygotic twin pairs discordant for BMIGraphical abstractHighlightsd Multiomics analyses of adipose tissue and skeletal muscle in
BMI-discordant twins
d Excess body weight downregulates mitochondrial pathways
in both tissues
d Excess body weight upregulates proinflammatory pathways
in both tissues
d Adipose tissue alterations are associated with metabolic
health in acquired obesityvan der Kolk et al., 2021, Cell Reports Medicine 2, 100226
April 20, 2021 ª 2021 The Authors.
https://doi.org/10.1016/j.xcrm.2021.100226Authors
Birgitta W. van der Kolk, Sina Saari,
Alen Lovric, ..., Adil Mardinoglu,






In adipose tissue and skeletal muscle of
BMI-discordant monozygotic twin pairs,
van der Kolk et al. demonstrate that
excess body weight is associated with
downregulated mitochondrial pathways
and upregulated proinflammatory
pathways. Furthermore, adipose tissue
metabolic alterations appear to be more
pronounced than those in muscle,
whereas only adipose tissue alterations
are associated with metabolic health.ll
OPEN ACCESS
llArticle
Molecular pathways behind acquired obesity:
Adipose tissue and skeletal muscle multiomics
in monozygotic twin pairs discordant for BMI
Birgitta W. van der Kolk,1,19,* Sina Saari,1,19 Alen Lovric,2,3 Muhammad Arif,2 Marcus Alvarez,4 Arthur Ko,5 Zong Miao,4,6
Navid Sahebekhtiari,1 Maheswary Muniandy,1 Sini Heinonen,1 Ali Oghabian,1 Riikka Jokinen,1 Sakari Jukarainen,7
Antti Hakkarainen,8 Jesper Lundbom,8,9 Juho Kuula,8,10 Per-Henrik Groop,11,12,13,14 Taru Tukiainen,7 Nina Lundbom,8
Aila Rissanen,1 Jaakko Kaprio,7 Evan G. Williams,15 Nicola Zamboni,15 Adil Mardinoglu,2,16 Päivi Pajukanta,4,6,17
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https://doi.org/10.1016/j.xcrm.2021.100226SUMMARYTissue-specific mechanisms prompting obesity-related development complications in humans remain un-
clear. We apply multiomics analyses of subcutaneous adipose tissue and skeletal muscle to examine the ef-
fects of acquired obesity among 49 BMI-discordant monozygotic twin pairs. Overall, adipose tissue appears
to bemore affected by excess body weight than skeletal muscle. In heavier co-twins, we observe a transcrip-
tional pattern of downregulated mitochondrial pathways in both tissues and upregulated inflammatory path-
ways in adipose tissue. In adipose tissue, heavier co-twins exhibit lower creatine levels; in skeletal muscle,
glycolysis- and redox stress-related protein andmetabolite levels remain higher. Furthermore,metabolomics
analyses in both tissues reveal that several proinflammatory lipids are higher and six of the same lipid
derivatives are lower in acquired obesity. Finally, in adipose tissue, but not in skeletal muscle, mitochondrial
downregulation and upregulated inflammation are associated with a fatty liver, insulin resistance, and dysli-
pidemia, suggesting that adipose tissue dominates in acquired obesity.INTRODUCTION
Obesity, a major public health burden, has increased globally,
doubling in prevalence in 70 countries between 1980 and 2015.1
Obesity predisposes individuals to a range of complex metabolicCell
This is an open access article unddiseases, including type 2 diabetesmellitus (T2DM), cardiovascu-
lar diseases, and some cancers.2 Triggers for obesity and related
adverse health outcomes vary remarkably between individuals
and are multifactorial, involving genetic and lifestyle factors in
the context of multiple social and environmental changes.Reports Medicine 2, 100226, April 20, 2021 ª 2021 The Authors. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1. Participant characteristics of 49monozygotic twin pairs
discordant for BMI with a mean age of 45.7 years (SD ± 17.8); 27





Body weight (kg) 75.8 ± 15.6 92.7 ± 17.9 <0.001
BMI (kg/m2) 26.2 ± 4.7 32.0 ± 5.5 <0.001
Body fat (%) 33.5 ± 9.0 41.1 ± 7.3 <0.001
Body fat (kg) 26.7 ± 10.9 39.0 ± 11.6 <0.001
Fat-free mass (kg) 47.5 ± 9.9 51.2 ± 11.7 <0.001





Intra-abdominal fat (cm3)a 552 (327–805) 1,146
(743–2214)
<0.001
Adipocyte volume (pl) 450 ± 192 637 ± 232 <0.001
Liver fat (%)a 0.6 (0.4–1.1) 2.7 (0.7–8.2) <0.001
Fasting glucose (mmol/L) 5.5 (5.0–5.8) 5.8 (5.2–6.0) 0.028
Fasting insulin (mU/L) 5.3 (3.3–7.3) 7.9 (5.4–12.4) <0.001
HOMA-IR index 1.1 (0.7–1.7) 2.0 (1.5–3.1) <0.001
Matsuda index 7.2 (4.7–9.6) 4.0 (2.7–5.2) <0.001
Total cholesterol (mmol/L) 4.8 ± 0.9 4.9 ± 1.0 0.401
HDL cholesterol (mmol/L) 1.6 (1.3–1.9) 1.4 (1.2–1.7) <0.001
LDL cholesterol (mmol/L) 2.9 ± 0.8 3.1 ± 0.9 0.117
Triacylglycerol (mmol/L) 0.9 (0.7–1.1) 1.3 (0.9–1.3) <0.001
CRP (mg/L) 1.4 (0.6–4.0) 1.7 (0.9–3.7) 0.182
Total physical activity
(Baecke)
8.4 (7.0–9.3) 7.9 (6.9–9.0) 0.350
Data are reported as mean ± SD (normally distributed variables) or
median (interquartile range for skewed variables). We used paired t tests
to calculate the p values and considered p < 0.05 significant. Skewed
variables were loge transformed before analysis. BMI, body mass index;
HDL, high-density lipoprotein; LDL, low-density lipoprotein; HOMA-IR,
homeostatic model for the assessment of insulin resistance; CRP,
C-reactive protein.
aData are based on 26 twin pairs.
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OPEN ACCESSObesity affects keymetabolic organs, including adipose tissue
and skeletal muscle, closely associated with metabolic health.3
Dysfunction of excess adipose tissue is characterized by
increased adipocyte size (hypertrophy),4 downregulation of
mitochondrial oxidative metabolism,5 impaired lipid buffering
capacity,6 and increased inflammation.7 Consequently, ectopic
lipid accumulation (because of saturation of adipose tissue stor-
age capacity), mitochondrial dysregulation, and low-grade
inflammation may contribute to development of skeletal muscle
and liver dysfunction, including diminished insulin sensitivity and
increased oxidative stress and inflammation.6,8
To date, few global omics studies have examined adipose
tissue and skeletal muscle separately to unravel the metabolic
alterations associated with obesity. Global transcriptomics
studies have shown significant adipose tissue dysregulation in
obesity and insulin resistance. The adipose tissue transcriptome
is characterized by downregulation of mitochondrion-related
pathways, including oxidative phosphorylation (OXPHOS),
branched-chain amino acid (BCAA) catabolism, fatty acid2 Cell Reports Medicine 2, 100226, April 20, 2021b-oxidation,9–11 and upregulation of inflammatory[9–13] and
extracellular matrix organization pathways.12,13 These findings
become more distinct among individuals with more pronounced
insulin resistance.11,13–15 Furthermore, microarray analyses of
mature adipocytes16–18 and metabolomics of adipose stem cell
cultures19 also revealed alterations in glucose and amino acid
metabolism, mitochondrial metabolism, and inflammation in
obesity.
In skeletal muscle tissue, several single omics analyses have
been performed, although they primarily focused on insulin
resistance and T2DM rather than obesity per se. Skeletal muscle
transcriptome analyses20,21 and transcriptome analyses from
isolated myoblasts22 from individuals with T2DM compared
with healthy controls identified downregulation of mitochondrial
pathways and myogenesis20–22 and upregulation of apoptosis
and inflammation.21 Similarly, in T2DM, lower mitochondrial
and amino acid metabolism protein levels and higher glycolysis-
and stress-related protein levels were found using proteomics
platforms.23–27 Less is known about perturbations in skeletal
muscle tissue metabolism in obesity without metabolic compli-
cations, although smaller proteomics studies suggest lower
mitochondrial protein levels in obesity even in the absence of
T2DM.24–27
To date, several studies have combined metabolic tissue
and/or plasma collections to identify biomarkers of insulin resis-
tance or T2DM,28–35 but only a few have specifically studied
obesity. A comprehensive global understanding of the underly-
ing mechanisms of obesity and the early stages of metabolic
complications at the whole-body and tissue-specific level is
currently lacking. Furthermore, the relative importance of adi-
pose tissue and skeletal muscle for development of concomitant
complications in obesity remains unclear, as do the roles of ge-
netics and lifestyle factors affecting obesity in tissuemetabolism.
Here we aimed to understand the tissue-specific biological
mechanisms and the relative tissue-specific importance under-
lying acquired obesity and related metabolic alterations. We
apply a multiomics framework to adipose tissue and skeletal
muscle by examining biological networks constructed using
RNA sequencing, proteomics, and metabolomics obtained
from 49 rare monozygotic twin pairs discordant for body mass
index (BMI); that is, when one twin is heavier than their co-
twin. These individuals share a genetic background as well as
most early life events and a family environment. Thus, our results
provide a global metabolic profile in obesity primarily dependent
upon acquired, environmental, and lifestyle factors.
RESULTS
Twin pairs highly discordant for clinical characteristics
of obesity
Table 1 summarizes the anthropometric andmetabolic character-
istics of leaner and heavier co-twins. The twin pairs, with a mean
weight difference of 17.1 ± 9.0 kg, were highly discordant (p <
0.001) for all measures of adiposity. In addition, the heavier co-
twins were more insulin resistant (p < 0.001) with higher plasma
triacylglycerol (TAG) concentrations (p < 0.001) and lower levels
of high-density lipoprotein (HDL) (p < 0.001), whereas the fasting
glucose level was only marginally higher in the heavier twin
Article
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OPEN ACCESS(p = 0.028). We detected no differences in total cholesterol, low-
density lipoprotein (LDL) cholesterol, C-reactive protein (CRP), or
physical activity levels between the heavier and leaner co-twins.
More transcripts were altered in adipose tissue than in
skeletal muscle
To understand the biological effect of the acquired excess body
weight, we first compared the adipose tissue and skeletal muscle
transcriptomes amongco-twins. In adipose tissue, among 14,558
identified genes, 3,454 transcripts were expressed differentially
between co-twins (false discovery rate [FDR] p < 0.05), with a total
of 1,615downregulated and 1,839upregulated genes in the heav-
ier co-twins (Table S1). The top 50 downregulated differentially
expressed genes included mitochondrial metabolism-related
genes (e.g., ACSS3, ETFA, MCCC2, and PCCA) and lipid meta-
bolism genes (SLC27A2, LPIN1, PPARA, HADH, and CIDEA).
The top 50 upregulated genes included inflammation-related
genes (IL1RN, C3AR1, CMSD2, and CD163).
In skeletal muscle, among 13,179 identified genes, we identi-
fied 1,287 differentially expressed genes between co-twins
(nominal p < 0.05, four genes with FDR p < 0.05), of which 665
were downregulated and 622 were upregulated in the heavier
co-twins (Table S2). The top 50 downregulated genes included
growth and nutrient-sensing genes (AKT1 and PDE4A) and mito-
chondrial membrane transport genes (HK2 and MCUR1). The
top 50 upregulated genes were linked to oxidoreductase activity
(NQO1) and lipid metabolism (THRSP and TYSND1).
KEGG pathway enrichment alterations in adipose tissue
and skeletal muscle
To gain insight into the differentially expressed transcriptome in
adipose tissue and skeletal muscle, we performed KEGG (Kyoto
Encyclopedia of Genes and Genomes) pathway enrichment an-
alyses. We observed consistent downregulation of mitochon-
drion-related metabolic pathways in the heavier co-twins in ad-
ipose tissue and skeletal muscle (Figure 1A). Upregulated
pathways in adipose and skeletal muscle tissue included the
extracellular matrix (ECM) remodeling pathways (Figure 1A).
In adipose tissue, we found multiple fatty acid metabolism
pathways, linked to lipid degradation among themost downregu-
lated pathways. Twenty-two inflammatory pathways were upre-
gulated significantly in the heavier co-twin (Figure 1B), including
pathways related to innate and adaptive inflammation, such as
the complement and coagulation cascades and Toll-like receptor
signaling and T cell receptor signaling pathways. Other upregu-
lated pathways were associated primarily with cell signaling.
In skeletal muscle tissue, we found 12 significantly different
pathways in co-twins (Figure 1C). Nutrient-sensing pathways,
including the insulin signaling pathway and autophagy, were
downregulated in the heavier co-twin along with metabolism of
several amino acids. The upregulated pathways in the skeletal
muscle tissue were involved in the N-glycan biosynthesis
pathway.
Downregulated transcripts for most genes in
mitochondrion-related pathways
Next, because mitochondrion-related metabolic pathways were
downregulated in both tissues, we inspected the individual tran-scripts of the significantly differentially expressed mitochondrial
pathways (Figure 1): OXPHOS, tricarboxylic acid (TCA) cycle, py-
ruvate metabolism, and BCAA (i.e., valine, leucine, and isoleu-
cine) degradation. The overall pattern clearly revealed that all
five complexes of OXPHOS were downregulated in adipose
and skeletal muscle tissue in the heavier co-twins (Figure 2).
The majority of TCA cycle-related, pyruvate metabolism, and
BCAA degradation genes tended toward downregulation in the
heavier co-twins in both tissues (Figure 2). Notable exceptions
included the upregulated cytosolic genes BCAT1 and SDS in
adipose tissue, which control BCAA degradation before mito-
chondrial oxidation.
Reporter metabolite analysis predicts alterations in
mitochondrial metabolites
We integrated the RNA sequencing data with genome-scale
metabolic models to gain insight into the subcellular localization
of the altered metabolic reactions as well as the reporter metab-
olites between co-twins.36,37 In adipose tissue, most of the re-
porter metabolites affected by transcriptional downregulation
in the heavier co-twin were mitochondrial (Figure 3A). Skeletal
muscle showed a similar, although less prominent pattern for
mitochondrial reporter metabolites associated with transcrip-
tional downregulation (Figure 3A). The reporter metabolites
associated with the transcriptional upregulation localized to the
lysosomes and Golgi apparatus for adipose tissue and skeletal
muscle (Figure 3A).
We then selected individual reporter metabolites (based on the
Metabolic Atlas38) involved in the significantly altered mitochon-
drial pathways, as shown in Figure 2. We found that the majority
of significantly altered reporter metabolites appeared in adipose
tissue (Figure 3B). For both tissues, significant reporter metabo-
lites in the mitochondrial pathways were transcriptionally down-
regulated in the heavier co-twins, with the exception of citrate [c]
for skeletal muscle, which was upregulated in the heavier co-
twins. The majority of OXPHOS and TCA cycle intermediates
were transcriptionally downregulated in the heavier co-twin in
adipose tissue. Pyruvate emerged as transcriptionally downre-
gulated in both tissues, particularly the downstream genes.
BCAA reporter metabolites were also identified as transcription-
ally downregulated, especially in adipose tissue. In summary,
adipose tissue exhibited a higher number of affected reporter
metabolites and, in both tissues, significant downregulation of
genes around OXPHOS, the TCA cycle, pyruvate, and BCAA
occurred in the heavier co-twins.
Tissue metabolomics alterations in adipose tissue and
skeletal muscle
To characterize the actual metabolome in acquired obesity, we
applied an untargeted metabolomics approach using mass
spectrometry, identifying 1,391 metabolites. In adipose tissue,
17 of 37 significantly altered metabolites (Table S3) and 21 of
63 significantly altered metabolites in skeletal muscle tissue
(Table S3) were lower in the heavier co-twins. Six lipid-related
metabolites were significantly lower in both tissues in the heavier
co-twins, including two oxylipins (Table S3).
In adipose tissue, metabolites with lower levels in the heavier
co-twins also included creatine, ATP, and taurocholic acid. TheCell Reports Medicine 2, 100226, April 20, 2021 3
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Figure 1. KEGG pathway enrichment analysis of differentially expressed genes in co-twins
(A) The heatmap presents pathways that are significantly different in both tissues.
(B) The heatmap presents significantly altered pathways in adipose tissue (n = 49 twin pairs).
(C) The heatmap presents significantly altered pathways in skeletal muscle (n = 44 twin pairs).
The direction and significance of each pathway was based on the gene set as a whole while considering the p value and fold change for each gene. KEGG
pathways with FDR p < 0.05 are shown; blue indicates significantly downregulated pathways in the heavier co-twins, whereas red indicates upregulated
pathways. Pathways are grouped according to their biological function. AT, adipose tissue; SkM, skeletal muscle; ECM, extracellular matrix.
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OPEN ACCESSmost significantly altered metabolite at higher levels consisted of
the ceramide species C18:Cer (Table S3).
In skeletal muscle, lower levels of metabolites in the heavier
co-twins were associated primarily with a variety of lipid interme-
diates (Table S3). Pyruvate emerged as the most significantly
altered metabolite, exhibiting higher levels in the heavier co-
twins, followed by several proinflammatory polyunsaturated fatty
acid-related eicosanoids (eicosadienoic acid, arachidonic acid,
leukotriene A4, and prostaglandin derivatives).
Comparison of mitochondrial metabolism in predicted
reporter and actual metabolites
Next, for the mitochondrial pathways, we compared the actual
metabolome results with the genome-scale metabolic models4 Cell Reports Medicine 2, 100226, April 20, 2021results; that is, the reporter metabolites. We only identified
two significantly different metabolites in the mitochondrial
pathways between co-twins. In adipose tissue, ATP levels
were lower in the heavier co-twins (Figure 4B), consistent
with the reporter metabolite analysis. In skeletal muscle, we
observed a transcriptional alteration around pyruvate in the
reporter metabolite analysis, which we confirmed with untar-
geted metabolomics, in which pyruvate levels were higher in
the heavier twins (Figure 4A). Interestingly, we observed higher
TCA intermediate levels downstream of pyruvate until a-keto-
glutarate in skeletal muscle (Figure 4A), whereas in adipose
tissue, the actual metabolome results point toward a consis-
tent pattern of lower TCA intermediate levels (Figure 4A), a




Figure 2. Heatmaps showing the differential expression of individual genes in four mitochondrial pathways among co-twins
The heatmaps show the downregulation in transcription levels for the majority of genes involved in the central mitochondrial pathways in AT (n = 49 twin pairs)
and SkM (n = 44 twin pairs). The log2-fold differences indicated for the genes are based on the KEGG pathways. The color in the heatmaps reflects the
differential expressions associated with the heavier co-twins, where blue indicates downregulation and red indicates upregulation. Asterisks indicate statistically




OPEN ACCESSNevertheless, the TCA or BCAA metabolites (Figure 4C) be-
tween leaner and heavier co-twins were not significantly
different in either tissue.
Differences in the skeletal muscle proteome related to
glycolysis and oxidative stress pathways
We also assessed the skeletal muscle proteome. We identified
881 proteins, 43 of which were significantly different between
co-twins (nominal p < 0.05; Table S4). Seven proteins had
lower expression levels in the heavier co-twins, including the
mitochondrial outer membrane protein CISD1 and two
proteins involved in cytoskeleton organization, FLNB and
MYL6B. The 36 proteins with a higher expression level in the
heavier co-twin were involved in stress and redox homeostasis
(PARK7, GLRX, and HSP90), generating pyruvate through
glycolysis (PFKP, PFKM, and PGK2), and converting pyruvate
to lactate (LDHA). The KEGG pathway enrichment analyses
indicated glycolysis (LDHA, PFKP, PFKM, and PGK2) as the
most significantly altered pathway (Table S5). The proteomics
results point toward a consistent pattern of higher levels of
glycolytic proteins in skeletal muscle (Figure 4D), although
we only identified a few that were significantly different be-
tween co-twins.Adipose tissue mitochondrial and inflammatory
pathways related to metabolic health
Following the transcriptome analyses in adipose tissue and skel-
etal muscle, we studied the relationship between four mitochon-
drial pathways (OXPHOS, the TCA cycle, pyruvate metabolism,
and BCAA degradation), three inflammation pathways (comple-
ment and coagulation cascade, phagosome, and T cell receptor
signaling pathways), and clinical outcomes among co-twins.
A combined score for genes in the mitochondrial pathways
was consistently associated negatively with multiple measures
for adiposity, such as subcutaneous adipose tissue volume
and the percentage of liver fat, insulin resistance (i.e., negatively
with the homeostatic model for the assessment of insulin resis-
tance (HOMA-IR) and positively with the Matsuda index), and
TAG and CRP in adipose tissue. However, we observed no
such associations with skeletal muscle (Figure 5). These correla-
tions were significant for the adiposity measures and tended to
be significant for insulin sensitivity measures when using the
within-pair differences for the measures; that is, controlling for
genetic influence (Figure 5). When analyzing twins as individuals,
all of these correlations were significant (Figure S1).
For the complement and coagulation cascade and phago-
some pathways, we observed a consistent pattern of positiveCell Reports Medicine 2, 100226, April 20, 2021 5
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Figure 3. Reporter metabolite representation for heavier co-twins
The reporter metabolites algorithmmarks the regions during metabolism around which significant transcriptional changes occur in AT (n = 49 twin pairs) and SkM
(n = 44 twin pairs). Reporter metabolites are obtained using the p values calculated from the comparison of heavier co-twins with leaner co-twins. A) Reporter
metabolites for the associated subcellular compartments and divided based on the direction (down/up) of the related gene sets (nominal p < 0.05) in the heavier
co-twins.
(B) Reporter metabolites associated with key mitochondrion-related pathways were compared between AT and SkM (nominal p < 0.05). The heatmap shows the
downregulated gene sets in the heavier co-twins that are significant in at least one of the tissues. In AT, no upregulated gene sets were associated with these




OPEN ACCESSassociations for multiple measures for adiposity, insulin resis-
tance, LDL, TAG, and CRP in adipose tissue, again observing
no associations in skeletal muscle, except for body fat percent-
age and high-density lipoprotein (HDL) (Figure 5). These results
imply that, in acquired obesity, mitochondrial and inflammatory
pathways correlate more closely with metabolic health in adi-
pose tissue than in skeletal muscle tissue.
Finally, we studied the relationship between significantly
altered metabolites in adipose tissue and skeletal muscle tissue
and clinical outcomes among co-twins (Table S6). For adipose
tissue, we found that creatine was significantly associated nega-
tively with multiple measures of adiposity, adipocyte size, insulin
resistance, and lipid metabolism, whereas the ceramide
C18:1Cer was associated positively with measures for adiposity
and HDL. For skeletal muscle, pyruvate was significantly posi-
tively associated with measures for adiposity and lipid meta-
bolism but not insulin resistance or adipocyte size. Furthermore,
skeletal muscle proinflammatory polyunsaturated fatty acid-
related eicosanoids were primarily significantly associated posi-
tively associated with measures for adiposity but not with other
clinical measurements. Last, we associated six previously unex-
plored lipid-related metabolites that were significantly lower in
both tissues in the heavier co-twins, including two oxylipins
(Table S6). Overall, these six lipid-relatedmetabolites were asso-6 Cell Reports Medicine 2, 100226, April 20, 2021ciated with multiple measures for adiposity and insulin resis-
tance in both tissues, with the exception of the oxylipin
9,12,13-trihydroxyoctadecenoic acid (TriHOME) in adipose
tissue.
DISCUSSION
This study describes a global metabolic profile in adipose tissue
and skeletal muscle characteristic of acquired obesity.We adop-
ted a novel approach by combining detailed phenotyping from
49 BMI-discordant monozygotic twin pairs with comprehensive
collections of adipose and skeletal muscle tissue samples using
multiomics and genome-scale metabolic modeling. Our results
predominantly reflect environmental and lifestyle factors, given
our unique BMI-discordant twin study design. Furthermore, our
study provides an opportunity to compare the role of adipose tis-
sue and skeletal muscle in the same individuals in development
of obesity-related complications.
Excess body weight was associated with transcriptional
downregulation of mitochondrial and nutrient-sensing pathways
as well as upregulation of inflammatory pathways in adipose tis-
sue and skeletal muscle in heavier co-twins compared with their
leaner co-twins (Figure 6). In skeletal muscle, we observed





Figure 4. Metabolites and proteins among co-twins in AT and SkM
(A–D) The direction (log2-fold changes) of the TCA cycle and pyruvate metabolite levels in the heavier co-twins (A), log2-fold changes of OXPHOSmetabolites (B),
log2-fold changes in the BCAA cyclemetabolite levels (C), and log2-fold changes of the glycolysis protein levels in SkM (D). AT (yellow, n = 47 twin pairs); SkM (red,
n = 40 twin pairs for metabolomics, n = 48 pairs for proteomics). **nominal p < 0.01, *nominal p < 0.05.
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OPEN ACCESSlactate dehydrogenase and pyruvate, as well as redox stress
proteins (Figure 6). In adipose tissue, we found lower creatine
levels. Furthermore, in both tissues, we identified higher levels
of multiple proinflammatory lipids and lower levels of the same
six lipid-related metabolites at the metabolome level. Overall,
the effects of surplus body weight appeared to be more pro-
nounced in adipose tissue than in skeletal muscle. Accordingly,
in adipose tissue, but not in skeletal muscle tissue, altered mito-
chondrial and inflammation pathways were associated with a
fatty liver, insulin resistance, and dyslipidemia.
One key finding was parallel transcriptional downregulation of
mitochondrial oxidative pathways in adipose tissue and skeletal
muscle. These pathways were downregulated more in adipose
tissue than in skeletal muscle. Because obesity is a significant
bioenergetic challenge to the body, it is often associated with
mitochondrial oxidative dysregulation. Indeed, lower transcript
and protein levels of mitochondria emerged consistently in both
tissues in obesity and T2DM using omics platforms.9–11,24–26,39
However, most studies have focused more on adverse metabolic
health aberrations than obesity per se, specifically among skeletal
muscle tissue studies. Because adipose tissue is a low-oxygen-
consuming tissue,40 it is slightly counterintuitive that adipose tis-
sue exhibits stronger downregulation of oxidative pathways thanskeletal muscle tissue in obesity. Nevertheless, our results agree
with two previous microarray-based studies.33,34 In those
studies, adipose tissue genes were expressed differentially than
genes in skeletal muscle tissue in insulin resistance (irrespective
of obesity) with downregulated mitochondrial catabolic path-
ways33,34 and upregulated inflammation.33 These findings indi-
cate that adipose tissue is a key metabolic tissue in acquired
obesity and that alterations in adipose tissue mitochondria may
precede those of skeletal muscle.
In addition to the well-known role of mitochondria in bioener-
getics, other vital metabolic functions of mitochondria include
generating anabolic precursors for macromolecules, producing
metabolic byproducts such as reactive oxygen species (ROS)
and lipid intermediates, and using mechanisms to clear or utilize
waste products.41 Our findings related to concomitantly downre-
gulated mitochondrial metabolism and upregulated inflamma-
tion in both tissues is intriguing and in line with previous findings
in adipose tissue9–11,33 and skeletal muscle.42 However, the
underlyingmechanisms for the two seemingly closely connected
biological phenomena remain unclear. Here we propose that
‘‘underachieving’’ mitochondria in acquired obesity give rise
to metabolic stress (e.g., increased ROS), accelerating inflam-
mation. Other possible mechanisms include fatty acid andCell Reports Medicine 2, 100226, April 20, 2021 7
A B
Figure 5. Within-pair associations of four mitochondrial and three inflammatory pathways with clinical outcome measures
(A) Standardized coefficients (bs) in linear mixedmodels with the delta clinical outcome between co-twins as the dependent variable, the delta for themitochondrial
and inflammatory pathways scores as the fixed effect, and family ID as a random effect and adjusted for sex, age, and diabetes status in AT (n = 49 twin pairs).
(B) Standardized coefficients (bs) in linear mixed models with the delta clinical outcomes between co-twins as the dependent variable, the delta for the mito-
chondrial and inflammatory pathways scores as the fixed effect, and family ID as a random effect and adjusted for sex, age, and diabetes status in SkM (n = 44
twin pairs).
Error bars denote 95% confidence intervals. BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TAG, triacylglycerol; HOMA-IR,
homeostatic model for the assessment of insulin resistance; CRP, C-reactive protein.
Article
ll
OPEN ACCESSceramide metabolism regulation and apoptosis by mitochon-
dria,43 processes we observed to be altered significantly in the
heavier co-twins and associated frequently with adipose tissue
inflammation.7 In addition, we observed upregulated lysosomal
and Golgi apparatus-related metabolic networks in both tissues,
identified similarly as closely related to dysregulated mitochon-
dria and inflammatory processes.44 Additional studies, however,
are needed to provide experimental evidence to support our pro-
posed causal link betweenmitochondria and obesity-associated
inflammation.
In skeletal muscle, our results suggest a shift in fuel partition-
ing frommitochondrial oxidation to cytosolic glycolysis with pref-
erential use of anaerobic glycolysis under normoxic conditions.
Alongside transcriptional mitochondrial oxidative downregula-
tion, we observed higher pyruvate levels in acquired obesity,
accompanied by higher glycolytic phosphofructokinases
(PFKM and PFKP) and LDHA protein levels. Higher skeletal mus-
cle glycolytic protein levels have been identified in women with
morbid obesity.45 Moreover, downregulated pyruvate uptake
into mitochondria has been associated with increased pyruvate
and circulating lactate levels in mice,46 leading to increased
whole-body energy expenditure. Another interesting finding
may be the pattern of higher TCA metabolites among heavier
co-twins up to alpha-ketoglutarate dehydrogenase. This finding
resembles glutamine-dependent reductive carboxylation,
discovered previously in several mammalian cell lines.47 In addi-
tion, reverse adaptation of the TCA cycle produces citrate and
lipids via glutamine-derived alpha-ketoglutarate. However, no8 Cell Reports Medicine 2, 100226, April 20, 2021conclusions regarding whether such metabolic routes occur in
the skeletal muscle of heavier co-twins can be made based on
the current data. Our data suggest an attempt to maintain ener-
getic and metabolic balance in the presence of excessive nutri-
ents in the early stages of obesity.
Interestingly, in adipose tissue, we also observed significantly
lower creatine levels in the heavier co-twins, accompanied by
the downregulated creatine transporter SLC6A8. Along with
the classically appreciated energy-buffering role (recycling
ATP) in skeletal muscle, recent work indicates that creatine has
a pleiotropic role in diverse cell types and physiological condi-
tions.48 For instance, in rodent brown adipose tissue, creatine
appears to closely link to mitochondria by controlling thermo-
genic respiration, and loss of this metabolite impaired whole-
body energy expenditure, leading to obesity.49 However, the
specific function of creatine in human white adipose tissue re-
mains unexamined. In addition, except for CIDEA, we did not
observe differences in markers of brown/beige adipose tissue
(e.g., UCP1 and PRDM16) between co-twins.
We also found that multiple metabolites of polyunsaturated
fatty acids were altered in acquired obesity. In skeletal muscle,
we detected high eicosanoid levels, known as powerful media-
tors of inflammation,50 in the heavier co-twins. In addition, in
both tissues, we found lower levels of potentially interesting
lipid-related metabolites, including two oxylipins (e.g., polyun-
saturated fatty acid derivatives) in the heavier co-twins. Overall,
these six lipid-related metabolites were associated with multiple
measures of adiposity and insulin resistance in both tissues, with
Figure 6. Summary of key metabolic differ-
ences in AT and SkM tissue metabolism in
acquired obesity
Results from AT (transcriptomics and metab-
olomics) and SkM (transcriptomics, proteomics,
and metabolomics) are included. Significant dif-
ferences between co-twins from proteomics are
indicated by P andmetabolomics by M (nominal p <
0.05). The color of the arrows reflects the differ-
ential expressions associated with the heavier co-
twins, where blue indicates downregulation, and
red indicates upregulation. OXPHOS, oxidative




OPEN ACCESSthe exception of the oxylipin 9,12,13-TriHOME in adipose tissue.
The function of these lipids remains unclear. So far, other oxyli-
pins appear to affect tissue differentiation processes,51 lipid
storage,52 or the process of adipocyte ‘‘browning.’’53 Experi-
mental studies should follow up on these results.
Finally, the finding that adipose tissue relates more to meta-
bolic health in acquired obesity than skeletal muscle is an impor-
tant message for prevention of obesity-related complications. In
adipose tissue, transcriptional mitochondrial downregulation
and inflammation upregulation are associated with a fatty
liver, insulin resistance, and dyslipidemia. This indicates that
metabolic alterations in adipose tissue function occur during
the early stages of the cascade of events, eventually leading to
metabolic diseases.5 Mitochondrial downregulation and upregu-
lated inflammation could accelerate adipose tissue dysfunction,
leading to ectopic lipid accumulation in the liver and skeletal
muscle with harmful sequelae, such as insulin resistance6 and
non-alcoholic fatty liver disease8.
The major strength of this work is that our BMI-discordant
monozygotic co-twin research design provides an outstanding,
well-controlled human study design closely matching genes,
age, sex, and the intrauterine and childhood environment
between the leaner and heavier groups. Hence, phenotypic dif-
ferences within a monozygotic twin pair can be attributed to ac-
quired (lifestyle) factors. Our study also uses a systems biology
approach in humans covering the transcriptome, proteome,
and metabolome in two key metabolic tissue types. This multio-
mics approach in a well-phenotyped BMI-discordant monozy-
gotic twin model with a large weight discordance (17.1 ±
9.0 kg, 5.8 kg/m2) allows us to investigate the (patho)physiolog-
ical responses of surplus body weight on adipose tissue and
skeletal muscle, independent of genetic factors.
We show that metabolic alterations in adipose tissue appear to
be more pronounced and more related to metabolic health than
skeletal muscle in acquired obesity. Furthermore, a key finding is
that mitochondrion-related and nutrient-sensing pathways were
downregulated in adipose tissue and skeletal muscle in acquired
obesity. Concomitantly, we observed simultaneous upregulation
of inflammatory pathways, particularly in adipose tissue.WeargueCell Rethat, because of a high nutrition load, adi-
pose tissue and skeletal muscle tissue no
longer sufficiently shift between catabolic
andanabolic reactions inacquiredobesity.
Consequently, the cells in these tissues in-crease their intracellular communication and activate emergency
responses such as inflammation. Mitochondria may serve as key
sensors of such processes. However, the underlyingmechanisms
that drive the observed differences inmetabolic functions of mito-
chondria and inflammation in obesity require further study.
Limitations of study
The primary limitation associated with the current study is its
cross-sectional nature. Although we can exclude genetic and
shared early environmental factors from the observed associa-
tions, our cross-sectional design prohibits causal inferences.
Furthermore, because the heavier co-twins exhibited poorer
metabolic health, some of the findings in our differential expres-
sion analyses may arise from obesity-associated metabolic dif-
ferences between the co-twins. Finally, another limitation of
the present study is that, for ethical reasons, we do not have
data regarding visceral adipose tissue, which previous studies
have found to be strongly associated with metabolic health.54
Experimental studies should follow up on these findings to fully
elucidate the biological mechanisms.
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pietilainen@helsinki.fi).
Materials availability
This study did not generate new unique reagents.
Data and code availability
RNA sequencing data are part of the ‘Twin Study’ and are deposited with the Biobank of the Finnish Institute for Health and Welfare
(https://thl.fi/en/web/thl-biobank/for-researchers/sample-collections/twin-study) with the identification number THLBB2021_001.
For details on accessing the data, see https://thl.fi/en/web/thl-biobank/for-researchers/application-process. All bona fide re-
searchers can apply for the data. The ImageJ macro used for measuring adipocyte diameters can be found at https://github.
com/birgittavdkolk/vanderkolk_etal_2021.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Twin participants
The twin pairs included in this study were recruited from population-based longitudinal studies, FinnTwin16 (n = 2839 pairs68) and
FinnTwin12 (n = 2578 pairs69), as well as the Older Finnish Twin Cohort (n = 2932 pairs36), based on their responses to questions
regarding weight and height.
Here, we included 49 monozygotic twin pairs discordant for BMI (within-pair difference, DBMIR 2.5 kg/m2), from two age groups
(27–42 years old and 57–69 years old) and for whom adipose tissue and skeletal muscle multiomics data were available. Twenty-
seven pairs were female. Eight pairs were discordant and four pairs were concordant for T2DM, while other pairs reported no T2DM.
The Ethics Committee of the Hospital District of Helsinki and Uusimaa approved the studies and all participants provided their writ-
ten informed consent. The studies adhered to the principles of the Declaration of Helsinki.
METHOD DETAILS
Study protocol
Participants arrived at the clinical research center the day before the studies. All participants were instructed by a nutritionist to
consume an isocaloric diet and to avoid strenuous exercise and alcohol consumption for two days prior to admission. Weight
and height were measured after a 12-h overnight fast in light clothing. Body composition was measured using dual-energy X-ray ab-
sorptiometry (software version 8.8; DEXA, Lunar Prodigy, Madison, WI, USA), subcutaneous and visceral adipose tissue volumes
using magnetic resonance imaging (MRI) and liver fat content using magnetic resonance spectroscopy (MRS). Physical activity
was measured using the Baecke questionnaire70.
Liver fat content
MRI and MRS experiments were performed on a 1.5 Tesla clinical imager (Avanto/Avantofit, Siemens, Erlangen, Germany). To deter-
mine the liver fat content, a 253 253 25mm3 voxel was placed in themiddle of the right liver lobe and liver spectra with an echo time
(TE) of 30 ms, collecting 4 averages. A point-resolved spectroscopy (PRESS) sequence was used for spatial localization, while signal
acquisition was triggered to end exhalation using a navigator belt to eliminate motion artifacts due to respiratory motion, maintained
at TR > 4000 ms. Liver spectra were analyzed with the jMRUI 6.0 software37 and the intensities of methylene and water resonances
were determined using the AMARES algorithm.67 Signal intensities were corrected for the relaxation effects and the liver fat was
calculated as an intensity ratio of methylene/(methylene+water). Ratios were further converted to mass fractions as described pre-
viously.71 All spectra were analyzed by a physicist blinded to the clinical data.
Intra-abdominal and subcutaneous fat
MRIs were recorded using the body coil as the transmitter and receiver. A stack of abdominal T1-weighted MRIs (16 slices, slice
thickness 10 mm, TR of 91 ms, TE of 5.2 ms and a flip angle of 80) were obtained from 8 cm above to 8 cm below the L4/5 lumbar
intervertebral disks using frequency-selective fat excitation. Areas of visceral and subcutaneous adipose tissue depots were deter-
mined from each slice using SliceOmatic (TomoVision, Quebec, Canada) version 5.0 segmentation software using the region-
growing routine.
Clinical chemistry
Blood samples were collected following an overnight fast. Whole blood, separated plasma and serum samples were frozen at80C
until further analysis. Samples were analyzed at the HUSLAB facilities using standardized methods. Concentrations of plasmae2 Cell Reports Medicine 2, 100226, April 20, 2021
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glucose/hexokinase, Roche Diagnostics, Basel, Switzerland) with a Hitachi Modular automatic analyzer and serum insulin with a
time-resolved immunofluorometric assay (Perkin Elmer, Waltham, MA, USA). Fasting plasma total cholesterol, high-density lipopro-
tein cholesterol (HDL) and triglyceride concentrations were determined using enzymaticmethods (RocheDiagnostics Hitachi, Hitachi
Ltd, Tokyo, Japan). Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula. Serum high-sensitivity
C-reactive protein (hs-CRP) was measured using the particle-enhanced immunoturbidimetric assay (Cobas CRP (Latex) HS, Roche
Diagnostics) on a Modular automatic analyzer (Hitachi Ltd, Tokyo, Japan).
Insulin sensitivity
Participants underwent a standard 4-point oral glucose tolerance test (OGTT). After an overnight fast, venous blood was sampled
before (t0) and after a 75-g glucose load was ingested. Blood samples were taken at the HUSLAB facilities at t0, t30, t60 and
t120 min to determine glucose and insulin concentrations. The homeostatic model assessment–insulin resistance index was calcu-
lated as (fasting glucose (mmol l1)3 fasting insulin (mU l1)/22.5). The Matsuda Index (ISI-M) = 10 000/(G0 3 I0 3 Gmean 3 Imean)
1/2,
where G and I represents plasma glucose [mmol dl1] and insulin [mU l1] concentrations, respectively, and ‘0’ and ‘mean’ indicate
the fasting value and mean value during OGTT, respectively.72
Adipose tissue and muscle biopsy collection
All biopsy collections took place during the fasting (12 h) state following collection of the fasting blood samples. The adipose tissue
and skeletal muscle biopsies were taken in sterile conditions under local anesthesia (lidocaine). The subcutaneous adipose tissue
biopsies were taken from superficial abdominal adipose tissue near the umbilicus using a surgical technique or through a needle bi-
opsy. A needle muscle biopsy was taken from the vastus lateralis muscle. An incision was made through the skin, after which the
sample was taken using a 5-mm Bergström needle.73 Both tissue specimens were immediately snap-frozen in liquid nitrogen and
stored in liquid nitrogen until further analysis.
Adipocyte size measurements
For part of the fresh subcutaneous adipose tissue biopsies, a collagenase digestion was performed. The subcutaneous adipose tis-
sue was minced and incubated for 1 h at 37C through constant shaking in 10 mL of an adipocyte medium (DMEM/F-12 (1:1) (Invi-
trogen, Paisley, UK) supplemented with 16-mmol l-1 biotin, 18-mmol l-1 panthotenate, 100-mmol l-1 ascorbate and antibiotic-antimy-
cotic (Invitrogen)), supplemented with 2% bovine serum albumin (Sigma, St Louis, MO, USA) and with 2-mg ml-1 collagenase A
(Roche, Basel, Switzerland). Digestion was stopped when the adipocyte medium supplemented with 10% newborn calf serum
(Sigma) was added, and centrifuged for 10 min at 600 g. After washing the adipocytes with an adipocyte medium, photographs
of the adipocytes were then taken using a light microscope (Zeiss, Axioplan2) at x50 magnification. Adipocyte diameters were auto-
matically measured from the images using a custom algorithm for ImageJ (ImageJ 1.42q/ Java 1. 6.0 10 32-bit; https://github.com/
birgittavdkolk/vanderkolk_etal_2021), which preprocessed the image to enhance the borders of the adipocytes and then used a
circle-detection algorithm to identify the cells. The algorithm was tuned to identify the adipocytes taken using the standardized
microscope settings, and validated against 2000 manually measured diameters from 20 pictures (r = 0.85, p < 0.001). Mean adipo-










. V = cell volume (mm3), d = cell
diameter (mm). Adipocytes were assumed to be spheres.
Adipose tissue and muscle transcriptomics
For total RNA extraction, we used ~250 mg of frozen adipose tissue and skeletal muscle biopsies. RNA was extracted using the
AllPrep RNA, DNA, miRNA Universal Kit (QIAGEN, Nordic, Solletuna, Sweden) with a DNase I (QIAGEN) digestion according to
the manufacturer’s instructions. The resulting DNA-free RNA samples were analyzed for quality on a 2100 Bioanalyzer according
to themanufacturer’s protocol (Agilent Technologies, Santa Clara, CA, USA). The RNA integrity numbers (RINs) were calculated auto-
matically using the 2100 expert software prior to RNA sequencing.
For the RNA sequencing, we prepared the libraries using Illumina Stranded mRNA preparation and sequenced the samples on the
Illumina HiSeq2000 platform to an average sequence depth of 40 to 50M paired-ends. We sequenced adipose tissue RNA reads to a
length of 75 bp and skeletal muscle RNA reads to a length of 69 bp. We aligned the reads from the samples against the human refer-
ence genome hg38 using STAR v2.5.2b and its two-pass protocol with Gencode v26 annotations.57 We required an RNaseq sample
to include at least 20 M uniquely mapped reads and the correct Library strandedness. The sample quality was assessed using Pic-
ard.74 To avoid mixing up samples, we matched the genotype array and RNaseq data using exonic SNPs with VerifyBamID.58 Read
counts were calculated using HTSeq v0.6.1p.59
Skeletal muscle proteomics analysis
For the total protein extraction, we first lysed skeletal muscle biopsies of ~15mg and homogenized in an RIPA-M buffer, followed by a
full lyse in 8 M urea. The cell pellet was spun down and the supernatant discarded, and, then, the protein was washed andCell Reports Medicine 2, 100226, April 20, 2021 e3
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tol and iodoacetamide to reduce and alkylate the sample, respectively, to prevent disulfide bonds. This was followed by overnight
trypsinization to create peptide fragments. The resulting peptide was then cleaned with a C18 spin column (Nest Group). Further
details and a step-by-step protocol for sample preparation appear elsewhere.75 Samples were then prepared for injection on an Ab-
Sciex 5600 coupled with an Eksigent LC by aliquoting 1 mg of peptide together with indexed retention-time peptides (Biognosys). The
samples were then acquired in SWATH mode with 64 windows on a 60-min gradient76 and processed using OpenSWATH v2.1.77,78
The analysis pipeline was recently published,78 and only briefly summarized here. Raw acquisition files (.wiff) from the mass spec-
trometer were converted to mzXML using Proteowizard 3.0.5533.65 Samples were searched with OpenSWATH v2.1 using the
PanHuman library.56 Peptides were filtered at a 1% FDR using Jumbo PyProphet v1.0. All 103 successful runs (including technical
replicates) were then aligned with TRIC (in the msproteomicstools 0.8.0 package on Github), yielding 9360 proteotypic peptides cor-
responding to 2935 unique proteins. Total protein levels were calculated using default parameters on mapDIA v3.0.2.66
Adipose tissue and muscle metabolomics
For both tissues, 20 to 80 mg of frozen tissue was homogenized under cold conditions by keeping them in a cold ethanol bath
(<20C). To homogenize the tissues, we added metallic beads and 0.5-mL cold (40C) extraction solvent (70% (v/v) 99.9% purity
ethanol in double-distilled water) to each sample and homogenized it at full speed for 1 min with TissueLyser. Thereafter, the homog-
enized samples were transferred to a new tube and 7mL of hot (75C) extraction solvent was added. The samples were incubated for
exactly 1 min in a hot water bath and thorough mixing was assured through quick cycles of vortexing. After 1 min, the tubes with
samples were vortexed quickly and transferred to a cold bath (< 20C). The samples were centrifuged for 10 min at 1000 g at
4C and a supernatant was transferred to a new tube, whereby no liquid remained in the old tube. The metabolite extracts were dried
under a vacuum at a maximum temperature of 30C, resuspended in 10 mL of ddH20 per mg and stored in a 80C freezer until
further analysis.
Then, we analyzed the metabolite extracts through flow injection–time-of-flight mass spectrometry analysis on an Agilent 6550
QTOF instrument (Agilent) in the negative mode at 4 GHz and in the high-resolution mode in the m/z range of 50 to 1000.79 Samples
were delivered in a 60:40 mixture of isopropanol:water supplemented with NH4F at pH 9.0 at a flow rate of 150 mL/min. Ions were
putatively annotated to metabolites based on an accurate mass within a 0.001-Da mass accuracy using the HMDB v3.0 database.55
This approach allowed us to infer the molecular formula of the detected metabolites, but not to distinguish between isomers.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses
We analyzed all data using SPSS for Mac (version 24.0; SPSS Inc., Chicago, IL, USA) or R statistical programming language (version
3.3.3). In the figure and table legends, we state the specific statistical used parameters as well as the number of included twin pairs
and the cutoff for statistical significance.
Participant characteristics
We assessed the anthropometric andmetabolic differences between twin pairs using paired t tests for continuous variables. Skewed
variables were loge-transformed before analysis.
Proteomics and metabolomics data preprocessing
Raw proteomics data were LOESS normalized, batch corrected at the peptide level and aggregated to the protein level based on the
most abundant peptide across samples. We imputed missing values by using the minimum value divided by a factor of 10. For
the raw metabolomics data, we matched data across both tissues for the participant. We collapsed all duplicated samples based
on the mean, followed by pareto scaling and log2-transforming the data.
80
Differential expression analysis
We performed differential expression analyses between co-twins using the R package Limma (Voom).60 Prefiltering of genes was
applied by retaining genes that have at least ten counts in 70% of samples and only selecting protein coding genes. We identified
the altered genes, proteins and metabolites that associated with the heavier compared with the leaner co-twin within each sample.
We adjusted the regression model for the sex, age group and diabetes status of the individuals. To ensure pairwise comparisons
between twins, we used the family ID as the identifier. We corrected p values for multiple testing (using the Benjamini and Hochberg
method) and, for the adipose tissue transcriptomics, we considered FDR p < 0.05 statistically significant. For adipose tissue metab-
olomics and for all skeletal muscle omics analyses, applying multiple test corrections proved statistically too conservative and
hampered the biological interpretation. Therefore, we considered nominal p < 0.05 significant for these datasets.
Biological pathway analyses
We investigated the significantly altered genes and proteins identified from the differential expression analyses using KEGG pathway
enrichment analyses. For the transcriptomics results, we used the PIANO package in R and the KEGG pathways gene-set collectione4 Cell Reports Medicine 2, 100226, April 20, 2021
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pressed proteins using STRING version 11.0 KEGG pathways, and considered FDR p < 0.05 statistically significant.
Genome-scale metabolic models
Wegenerated genome-scalemetabolicmodels based on the transcriptomics data to extract the so-called reportermetabolites using
PIANO61 as well as the iAdipocytes180963 and iMyocyte241964 models for the adipose tissue and skeletal muscle, respectively.
These models represent a list of metabolic equations incorporated into a network that links common metabolites. The metabolic
equations relate to the genes coding for each particular protein in themetabolic reaction, while reporter metabolites are also assigned
to the appropriate cellular compartment. Reporter metabolites with nominal p < 0.05 were considered significant.
Associations with clinical variables
To analyze how mitochondrial and inflammation pathways associated with clinical variables, we calculated four mitochondrial and
three inflammation pathway scores by averaging the z-scores of the associated genes in the KEGG pathways for each co-twin. We
calculated the standardized beta coefficients between these four mitochondrial KEGG pathway scores, three inflammation KEGG
pathway scores, selected metabolites and the clinical measures using a linear mixed-model analysis. We repeated the analysis,
examining the within-pair differences in the variables, which allowed us to control for genetic influences. Family ID was used as a
random factor and we adjusted the model for sex, age and diabetes status. Skewed clinical variables were loge-transformed.Cell Reports Medicine 2, 100226, April 20, 2021 e5
